文献速递神经免疫

高剂量辛伐他汀对继发进展型多发性硬化认知、神经精神及健康相关生活质量的影响:MS-STAT随机安慰剂对照试验的二次分析

Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial.
PubMed 文献 · Lancet Neurol · 2017-06-07

MS-STAT试验的二次分析纳入70例辛伐他汀80mg与70例安慰剂治疗的继发进展型多发性硬化患者,随访24个月。其他认知、神经精神及生活质量指标未见显著组间差异。

要点

  • 辛伐他汀80mg/日可能改善继发进展型多发性硬化的额叶功能。
  • 辛伐他汀可能改善躯体健康相关生活质量,但证据有限。
  • 其他认知、神经精神及生活质量指标未见显著获益。

核心结论

  • 辛伐他汀对额叶功能和躯体生活质量有潜在正向效应,但其他指标无显著效果,需进一步验证。

研究设计与样本

  • MS-STAT试验的二次分析,24个月双盲随机安慰剂对照,英国3个神经科学中心,2008年1月28日至2011年11月4日。
  • 患者按1:1随机分配至辛伐他汀80mg组(n=70)或安慰剂组(n=70),意向性分析。
  • 认知评估包括NART、WASI、GNT、BMIPB、VOSP(立方体分析)、FAB和PASAT;神经精神评估用HDRS和NPI-Q;生活质量用SF-36 v2。
  • 评估时间点为基线、12个月和24个月,患者、治疗医生和结局评估者均设盲。

主要发现

  • 基线时133例中60例(45%)FAB评测提示额叶功能损害,130例中13例(10%)至43例(33%)BMIPB评测提示非言语和言语记忆损害。
  • 其他结局指标未观察到治疗效应。

临床怎么用

  • 对于继发进展型多发性硬化患者,辛伐他汀可能作为改善额叶功能和躯体生活质量的辅助治疗选择,但需个体化评估。
  • 应重视进展型多发性硬化治疗试验中认知和生活质量的全面评估。

局限性

  • 本研究为二次分析,认知、神经精神及生活质量指标非主要终点,结果需谨慎解读。
  • 样本量较小(每组70例),可能不足以检测其他指标的微小差异。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the 24-month MS-STAT phase 2 trial, we showed that high-dose simvastatin significantly reduced the annualised rate of whole brain atrophy in patients with secondary progressive multiple sclerosis (SPMS). We now describe the results of the MS-STAT cognitive substudy, in which we investigated the treatment effect on cognitive, neuropsychiatric, and health-related quality-of-life (HRQoL) outcome measures. METHODS: We did a secondary analysis of MS-STAT, a 24-month, double-blind, controlled trial of patients with SPMS done at three neuroscience centres in the UK between Jan 28, 2008, and Nov 4, 2011. Patients were randomly assigned (1:1) to either 80 mg simvastatin (n=70) or placebo (n=70). The cognitive assessments done were the National Adult Reading Test, Wechsler Abbreviated Scale of Intelligence, Graded Naming Test, Birt Memory and Information Processing Battery (BMIPB), Visual Object and Space Perception battery (cube analysis), Frontal Assessment Battery (FAB), and Paced Auditory Serial Addition Test. Neuropsychiatric status was assessed using the Hamilton Depression Rating Scale and the Neuropsychiatric Inventory Questionnaire. HRQoL was assessed using the self-reported 36-Item Short Form Survey (SF-36) version 2. Assessments were done at study entry, 12 months, and 24 months. Patients, treating physicians, and outcome assessors were masked to treatment allocation. Analyses were by intention to treat. MS-STAT is registered with ClinicalTrials.gov, number NCT00647348. FINDINGS: Baseline assessment revealed impairments in 60 (45%) of 133 patients on the test of frontal lobe function (FAB), and in between 13 (10%) and 43 (33%) of 130 patients in tests of non-verbal and verbal memory (BMIPB). Over the entire trial, we noted significant worsening on tests of verbal memory (T score decline of 5·7 points, 95% CI 3·6-7·8; p<0·0001) and non-verbal memory (decline of 6·8 points, 4·8-8·7; p<0·0001). At 24 months, the FAB score was 1·2 points higher in the simvastatin-treated group than in the placebo group (95% CI 0·2-2·3). The simvastatin group also had a 2·5 points better mean physical component score of the SF-36 (95% CI 0·3-4·8; p=0·028). A treatment effect was not noted for any other outcomes. INTERPRETATION: To our knowledge, this SPMS cohort is the largest studied to date with comprehensive longitudinal cognitive, neuropsychiatric, and HRQoL assessments. We found evidence of a positive effect of simvastatin on frontal lobe function and a physical quality-of-life measure. Although we found no effect of simvastatin on the other outcome measures, these potential effects warrant confirmation and underline the importance of fully assessing cognition and quality of life in progressive multiple sclerosis treatment trials. FUNDING: The Moulton Foundation, the Berkeley Foundation, the Multiple Sclerosis Trials Collaboration, the Rosetrees Trust, a personal contribution from A W Pidgley CBE, and the National Institute for Health Research University College London Hospitals Biomedical Research Centre and University College London.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Chan D, Binks S, Nicholas JM, et al. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. Lancet Neurol. 2017. PMID: 28600189. doi:10.1016/S1474-4422(17)30113-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。